Prusogliptin
Clinical data | |
---|---|
Other names | DBPR108 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H25FN4O2 |
Molar mass | 324.400 g·mol−1 |
3D model (JSmol) | |
| |
|
Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.[1][2][3]
References
- ^ Xu, Jianping; Ling, Hongwei; Geng, Jianlin; Huang, Yanli; Xie, Ying; Zheng, Huiping; Niu, Huikun; Zhang, Tianhao; Yuan, Jing; Xiao, Xinhua (November 2022). "Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes: A 24-week, multi-centre, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial". Diabetes, Obesity and Metabolism. 24 (11): 2232–2240. doi:10.1111/dom.14810. PMC 9796963. PMID 35791646.
- ^ Yeh, Kai-Chia; Yeh, Teng-Kuang; Huang, Chung-Yu; Hu, Chih-Bo; Wang, Min-Hsien; Huang, Yu-Wen; Chou, Ling-Hui; Ho, Hsuan-Hui; Song, Jen-Shin; Hsu, Tsu; Jiaang, Weir-Torn; Chao, Yu-Sheng; Chen, Chiung-Tong (August 2021). "DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity". Life Sciences. 278: 119574. doi:10.1016/j.lfs.2021.119574. PMID 33961850. S2CID 233999305.
- ^ Wang, Wei; Yao, Jun; Guo, Xiaohui; Guo, Yushan; Yan, Chaoli; Liu, Kuanzhi; Zhang, Ying; Wang, Xiaoyue; Li, Hongmei; Wen, Zhongyuan; Wang, Xinling; Li, Shuangqing; Xiao, Xinhua; Liu, Weijuan; Li, Ziling; Zhang, Lihui; Shao, Shiying; Ye, Shandong; Qin, Guijun; Li, Yiming; Li, Feng; Zhang, Xiaomei; Li, Xuefeng; Peng, Yongde; Deng, Hongyan; Xu, Xiangjin; Zhou, Ligang; Huang, Yanli; Cao, Mengya; Xia, Xuefang; Shi, Mingbiao; Dou, Jing; Yuan, Jing (2 July 2020). "Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial". Current Medical Research and Opinion. 36 (7): 1107–1115. doi:10.1080/03007995.2020.1761311. PMID 32338063. S2CID 216555956.